...CMO. He was VP, head of oncology clinical research, clinical research development at bluebird bio Inc. (NASDAQ:BLUE).Silence Therapeutics plc...
...arrives, at which time he will join the board and become president-emeritus. BC Staff Moderna Inc. MorphoSys AG Allen Institute Silence Therapeutics plc Verastem...

...established cardiovascular disease.Leqvio inclisiran, an siRNA against PCSK9 from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Novartis AG (NYSE:NVS; SIX:NOVN) and Silence Therapeutics plc...

...CTO. He worked with the cancer and endocrine/metabolic company on a consultancy basis for the past year.siRNA play Silence Therapeutics plc (NASDAQ:SLN...
...Aspen Neuroscience Inc. and Gossamer Bio Inc. (NASDAQ:GOSS). Danielle Golovin GlaxoSmithKline plc Dr. Reddy's Laboratories Ltd. Mylan N.V. Rhythm Pharmaceuticals Inc. Silence Therapeutics plc Monte...

...head of global research and development and CSO at Santen Inc. CFO Rob Quinn will leave Silence Therapeutics plc...

...post at Trishula Therapeutics last month (see “Gilead Places Latest Bet on Cancer Immunosuppression”).siRNA company Silence Therapeutics plc...
...as chief commercial officer and head of international for the past two years. Jeff Cranmer Tizona Therapeutics Inc. Silence Therapeutics plc Rhythm...

...programs for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy.London-based Silence Therapeutics plc...
...growth factor β 3VEGF – Vascular endothelial growth factor BC Staff AVID200 Takeda Pharmaceutical Co. Ltd. Blackstone Group BeiGene Ltd. Prelude Therapeutics Inc. Silence Therapeutics plc Sirnaomics...

...The cancer company lost $0.25 (14%) to $1.59 on Tuesday. Silence planning NASDAQ listing London-based Silence Therapeutics plc...
...to this report. Targets TLR3 - Toll-like receptor 3 Robin Sawka, Staff Writer Robin Sawka, BioCentury Staff Geron Corp. Silence Therapeutics plc Arvelle...

...in RNA therapeutics as the company establishes its foothold in the modality through external innovation. Silence Therapeutics...
...cardiovascular and rare disease indications. Targets VEGF-A - Vascular endothelial growth factor A Lauren Martz, Senior Editor Silence Therapeutics plc [MERGED]...

...Ltd. appointed David Horn Solomon as chairman, succeeding Gaby Salem. Horn Solomon was CEO at Silence Therapeutics plc...

...and CFO. He was SVP and CFO of Agile Therapeutics Inc. (NASDAQ:AGRX). RNA therapy company Silence Therapeutics plc...
...become president of the liposome delivery company. Jonathan Block, Associate Editor Allogene Therapeutics Inc. CymaBay Therapeutics Inc. LipoMedix Pharmaceutical Inc. Silence Therapeutics plc Aprea...